• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    OPKO Health Inc. filed SEC Form 8-K: Leadership Update

    5/29/25 5:00:31 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OPK alert in real time by email
    8-K
    0000944809false00009448092025-05-272025-05-27

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 27, 2025

     

     

    OPKO Health, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-33528

    75-2402409

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    4400 Biscayne Blvd.

     

    Miami, Florida

     

    33137

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: 305 575-4100

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock

     

    OPK

     

    Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    On May 27, 2025, the Compensation Committee of the Board of Directors (the “Committee”) of OPKO Health, Inc. (the “Company”) held a meeting to review certain compensation matters for the Company’s executive officers and non-executive employees. At the meeting, the Committee (i) granted stock options to the Company’s named executive officers (the “Officers”) to purchase the number of shares of the Company's common stock set forth opposite their names below and (ii) approved bonus payments to employees, including the Officers named below in the amounts set forth opposite their names. The stock options have an exercise price of $1.31 per share, vest ratably on an annual basis over four years, and expire on the tenth anniversary of the grant date.

     

    Name

    Title

    Stock Options

    Bonus

    Phillip Frost, M.D.

    Chief Executive Officer/Chairman

    500,000

     

    $480,000

    Jane H. Hsiao, Ph.D.

    Vice Chairman/Chief Technical Officer

    500,000

     

    $450,000

    Elias A. Zerhouni, M.D.

    Vice Chairman/President

    500,000

     

    $450,000

    Steven D. Rubin

    Executive Vice President - Administration

    437,500

     

    $400,000

    Adam Logal

    Senior Vice President/Chief Financial Officer

    437,500

     

    $475,000

     

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    OPKO Health, Inc.

     

     

     

     

    Date:

    May 29, 2025

    By:

    /s/ Steven D. Rubin

     

     

    Name:

    Steven D. Rubin

     

     

    Title:

    Executive Vice President - Administration

     


    Get the next $OPK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OPK

    DatePrice TargetRatingAnalyst
    4/25/2025Neutral
    Analyst
    6/29/2023$2.00Mkt Perform → Outperform
    Barrington Research
    12/15/2022$3.00Buy
    H.C. Wainwright
    1/24/2022Outperform → Market Perform
    Barrington Research
    More analyst ratings

    $OPK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • OPKO Health to Participate in the 3rd Annual Piper Sandler Virtual Obesity Symposium

      MIAMI, June 25, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) today announced its participation in the 3rd Annual Piper Sandler Obesity Symposium being held virtually on June 26, 2025. Management will be participating in a fireside discussion moderated by Edward Tentoff, Managing Director, Senior Biotechnology Analyst. Investors can register for the symposium by contacting their Piper Sandler representative. About OPKO Health OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and novel and propriet

      6/25/25 11:00:00 AM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting

      MIAMI and JERUSALEM, June 25, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) and Entera Bio Ltd. (NASDAQ:ENTX) ("Entera") today announced that new pharmacologic and pharmacokinetic in vivo data for investigational oral OPK-88006 tablet treatment has been selected for presentation at the ENDO 2025 annual meeting of the Endocrine Society, taking place July 12-15, 2025 in San Francisco, CA, USA. Oral OPK-88006 is being developed pursuant to a collaboration and license agreement between OPKO and Entera whereby the companies are advancing a proprietary novel dual agonist GLP-1/glucagon peptide as a once-daily tablet treatment and as a weekly subcutaneous injection for patients with

      6/25/25 8:00:00 AM ET
      $ENTX
      $OPK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • OPKO Health's ModeX Therapeutics Announces Formation of Scientific Advisory Board with Leaders at the Forefront of Immunology and Oncology Drug Development

      Will provide expertise across ModeX's portfolio of next generation multispecific antibodies for complex diseases involving the immune system, including cancer ModeX's promising immunology pipeline includes first-in class drugs with two assets in ongoing clinical trials and multiple pre-IND assets to enter clinical trials WESTON, Mass., June 09, 2025 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ:OPK), today announced the creation of a Scientific Advisory Board to provide counsel and insight into the development of ModeX's immunology and oncology-focused pipeline featuring potential first-in-class multispecific antibodies and vaccines developed with its propri

      6/9/25 8:00:00 AM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OPK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Analyst initiated coverage on Opko Health

      Analyst initiated coverage of Opko Health with a rating of Neutral

      4/25/25 8:32:28 AM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Opko Health upgraded by Barrington Research with a new price target

      Barrington Research upgraded Opko Health from Mkt Perform to Outperform and set a new price target of $2.00

      6/29/23 9:11:26 AM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Opko Health with a new price target

      H.C. Wainwright initiated coverage of Opko Health with a rating of Buy and set a new price target of $3.00

      12/15/22 8:08:28 AM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OPK
    SEC Filings

    See more
    • OPKO Health Inc. filed SEC Form 8-K: Leadership Update

      8-K - OPKO HEALTH, INC. (0000944809) (Filer)

      5/29/25 5:00:31 PM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by OPKO Health Inc.

      10-Q - OPKO HEALTH, INC. (0000944809) (Filer)

      5/1/25 4:04:56 PM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OPKO Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - OPKO HEALTH, INC. (0000944809) (Filer)

      4/30/25 4:07:22 PM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OPK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO & Chairman Frost Phillip Md Et Al bought $169,712 worth of shares (125,000 units at $1.36) (SEC Form 4)

      4 - OPKO HEALTH, INC. (0000944809) (Issuer)

      4/10/25 5:07:15 PM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO & Chairman Frost Phillip Md Et Al bought $184,650 worth of shares (125,000 units at $1.48) (SEC Form 4)

      4 - OPKO HEALTH, INC. (0000944809) (Issuer)

      4/8/25 5:34:21 PM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO & Chairman Frost Phillip Md Et Al bought $164,850 worth of shares (100,000 units at $1.65) (SEC Form 4)

      4 - OPKO HEALTH, INC. (0000944809) (Issuer)

      4/1/25 5:21:45 PM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care